PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
February 22, 2026Clinical Cancer Research

Abstract PS2-10-19: Circulating tumor DNA (ctDNA) as a strong prognostic biomarker of minimal residual disease (MRD) using a tissue-free, epigenomic assay in early-stage breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

WJW. JanniUniversity Hospital UlmBRBrigitte RackLMU KlinikumPFP. A. FaschingUniversitätsklinikum Erlangen

Discussion

Loading...

Member takes

Overview

Clinical analysis confirms ctDNA predicts distant recurrence in early-stage breast cancer, indicating potential for targeted interventions.

Key Points

  • To assess the prognostic value of ctDNA in predicting distant metastatic recurrence in early-stage breast cancer patients.
  • Analyzed plasma samples from 359 patients with stage I-III breast cancer.
  • Employed the Guardant Reveal assay with an updated bioinformatics algorithm for ctDNA detection.
  • Samples re-analyzed approximately two years post-adjuvant chemotherapy in patients without prior disease recurrence.
  • 87.2% of samples were evaluable; ctDNA positivity rate of 5.8%.
  • ctDNA positivity was linked to significantly shorter distant recurrence-free intervals and poorer overall survival (HR 33.3, p<0.0001).
  • Sensitivity for detecting distant recurrence was 73%, with 94% of ctDNA-positive patients developing recurrences within 7.9 months of detection.

Cite This Study

Janni et al. (2026) studied this question.

synapsesocial.com/papers/699a9de0482488d673cd4130https://doi.org/10.1158/1557-3265.sabcs25-ps2-10-19
View Full Paper
Ask AI
Bookmark
Share